Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
33 Results for "
cervical adenocarcinoma
" in MedChemExpress (MCE) Product Catalog:
Products (33)
33 Results for "cervical adenocarcinoma" in MCE Product Catalog:
1
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-168022
CAS No.: 3056388-47-4
Target:
Research Areas:
CAM2602 is an orally active Aurora A-TPX2 protein−protein interaction inhibitor with a human Kd of 19 nM for Aurora A. CAM2602 increases the proportion of PH3 positive cells while reducing P-T288 Aurora A levels. CAM2602 arrests tumor xenograft growth in mice. CAM2602 can be used for the research of cancer, such as acute T cell leukemia .
Dyrk1A-IN-4 is a potent and orally active Dyrk1A inhibitor. Dyrk1A-IN-4 exhibits IC50s against DYRK1A and DYRK2 of 2 nM and 6 nM. Dyrk1A-IN-4 exhibits the inhibition of the DYRK1A pSer520 autophosphorylation in U2OS cells with an IC50 of 28 nM. Dyrk1A-IN-4 can be used for the studies of ovarian adenocarcinoma, neuroblastoma and cervical squamous cell carcinoma .
Cat. No.: HY-169325
Target:
Research Areas:
(S)-ACE‑OH is the active metabolite of Acepromazine (HY-B1506), acting as a molecular glue degrader. (S)-ACE-OH induces functional interaction between TRIM21 and NUP98, promoting protein ubiquitination and degradation of TRIM21 at the nuclear pore complex. (S)-ACE-OH triggers nucleocytoplasmic transport disorder and exerts interferon-potentiated cytotoxic effects on certain cancer cells. (S)-ACE-OH can be used in cancer-related research .
Cat. No.: HY-N5008
CAS No.: 146100-02-9
Cat. No.: HY-W014989
CAS No.: 20408-97-3
SHP2 protein degrader-1 is a potent SHP2 PROTAC degrader with an IC50 of 0.714 μM. SHP2 protein degrader-1 inhibits cancer cell growth and induces apoptosis. SHP2 protein degrader-1 can be used in cervical adenocarcinoma research .
Cat. No.: HY-130645
CAS No.: 2410557-01-4
iRucaparib-TP3 is a non-trapping PARP1 PROTAC degrader with concurrent PARP1 catalytic inhibitory activity. iRucaparib-TP3 induces PARP1 ubiquitination and subsequent proteasomal degradation. iRucaparib-TP3 can be used for the research of cervical adenocarcinoma .
Cat. No.: HY-W004616
CAS No.: 610-92-4
Target:
Research Areas:
2,5-Dihydroxyterephthalic acid is a carboxylic acid ligand with antioxidant properties, which serves as a building block for Zn 2+-based metal-organic frameworks (MOFs). 2,5-Dihydroxyterephthalic acid forms stable coordination bonds with transition metal ions, inhibits metal center-water coordination to prevent MOF fluorescence quenching, and enhances the hydrophilicity of MOFs. 2,5-Dihydroxyterephthalic acid acts as a pharmaceutical intermediate to synthesize 2,5-dihydroxyterephthalamide derivatives. 2,5-Dihydroxyterephthalic acid is applicable to relevant research in fields such as organic synthesis .
Cat. No.: HY-145866
Target:
Research Areas:
Antiproliferative agent-3 is an antiproliferative agent. Antiproliferative agent-3 exhibits anticancer activity against a variety of cancers, including estrogen receptor-positive breast cancer. Antiproliferative agent-3 shows no toxicity to wild-type zebrafish embryos. Antiproliferative agent-3 can be used in the research of chronic myeloid leukemia, promyelocytic leukemia, Burkitt's lymphoma, estrogen receptor-positive mammary adenocarcinoma, cervical cancer, and lung cancer .
Cat. No.: HY-179016
Research Areas:
Ferroptosis/apoptosis inducer-3 (Compound 34) is a Ferroptosis and Apoptosis inducer. Ferroptosis/apoptosis inducer-3 induces both Ferroptosis and Apoptosis by causing G2/M phase cell cycle arrest, disrupting mitochondrial membrane potentials, promoting lipid peroxidation, and increasing the levels of Ca 2+ and Fe 2+ through the activation of calcium/calmodulin signaling. Ferraplasm/apoptosis inducer-3 shows anticancer effects against cervical cancer, adenocarcinoma, breast cancer, colon cancer, and colorectal carcinoma .
Cat. No.: HY-D2336
CAS No.: 3038774-43-2
PROTAC Aster-A degrader-1 is a PROTAC degrader targeting the sterol transporter (Aster-A), with a DC50 of 4.8 μM. PROTAC Aster-A degrader-1 binds to the sterol-binding domain of Aster-A, with a FI-Kd value of 83 nM. PROTAC Aster-A degrader-1 induces CRL- and proteasome-dependent degradation of Aster-A and inhibits autophagy in cancer cells. PROTAC Aster-A degrader-1 serves as a fluorescent probe. PROTAC Aster-A degrader-1 is useful for research related to cervical cancer, breast cancer, and lung adenocarcinoma .
Cat. No.: HY-P2044
CAS No.: 585535-37-1
Category:
Target:
Cat. No.: HY-184750
Target:
Research Areas:
Anticancer agent 337 (compound 5n) is a topoisomerase I inhibitor. Anticancer agent 337 inhibits topoisomerase I activity in a concentration-dependent manner, suppresses cancer cell migration, induces apoptosis, and arrests the cell cycle at the G1 phase. Anticancer agent 337 can be used in the research of lung cancer, hepatocellular carcinoma, and cervical adenocarcinoma .
Cat. No.: HY-N19312
CAS No.: 28164-57-0
Category:
Quinones Ebenaceae Phenols Polyphenols Benzene Quinones Plants
Cat. No.: HY-181272
MMP-9-IN-14 is a MMP-9 inhibitor (IC50 = 34.46 μM). MMP-9-IN-14 induces G1-phase cell cycle arrest and caspase-dependent apoptosis in cancer cells. MMP-9-IN-14 promotes the accumulation of phosphorylated γH2AX. MMP-9-IN-14 inhibits the migration and invasion of cancer cells, and downregulates the expressions of MMP-2, MMP-9 and hTERT in cancer cells. MMP-9-IN-14 inhibits tumor growth and angiogenic spread in animal models. MMP-9-IN-14 can be used for the research of cancers such as lung adenocarcinoma, cervical cancer and colorectal cancer .
Cat. No.: HY-182760
Research Areas:
MN33-63 is a Bcl-2 inhibitor, caspase-3 activator and DNA crosslinker with broad-spectrum anticancer activity. MN33-63 improves the water solubility of SN-38 (HY-13704), inhibits tumor growth and proliferation in a dose-dependent manner, and causes no obvious toxicity. MN33-63 relieves the inhibition of the mitochondrial apoptotic pathway, initiates the apoptosis program, inhibits Topo I activity, and promotes its degradation via the ubiquitin-proteasome and autophagy-lysosome pathways. MN33-63 induces DNA crosslinking, G2/M cell cycle arrest, inhibition of cancer cell migration, and cancer cell apoptosis through the mitochondrial pathway. MN33-63 can be used in the research of colorectal cancer, cervical cancer, hepatocellular carcinoma, lung adenocarcinoma and gastric cancer .
Cat. No.: HY-118606
CAS No.: 296246-47-4
LDN-0044878 is a PAK3 inhibitor. LDN-0044878 inhibits the proliferation or induces the death of p53-deficient cells. LDN-0044878 exhibits moderate trypanocidal activity against Trypanosoma brucei, but does not directly inhibit the core target Rhodesain. LDN-0044878 can be used in studies related to cervical adenocarcinoma and Trypanosoma brucei infection.
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
